ClinicalTrials.gg
CompletedNCT00112047Updated Oct 13, 2010Results posted

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

A Phase 3 interventional study of Emtricitabine (FTC) and Tenofovir Disoproxil Fumarate (TDF) in HIV Infections, sponsored by Gilead Sciences. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-10-13.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing emtricitabine in HIV Infections — 4 open to participants now, 8 under way, 4 of them phase 3. Emtricitabine · HIV Infections.

Enrollment
12th of 63
517 · median 100
Started
2003
the only one that year
Phase 3
17 of 65
1 open now
Registered
11th of 65
by date
Lead sponsor
14 of 65
Gilead Sciences

Among the 65 studies testing emtricitabine in HIV Infections, this one is the 12th largest by enrollment of the 63 interventional ones that give a count, is the only one that started in 2003, is one of 17 in phase 3, and was the 11th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 65 studies testing emtricitabine in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About emtricitabine

Emtricitabine: first FDA approval 2003 (EMTRIVA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing emtricitabine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants. The primary objective of the study was to assess noninferiority of emtricitabine (FTC) and tenofovir disoproxil fumarate (tenofovir DF; TDF) in combination with efavirenz (EFV) relative to Combivir (CBV) in combination with EFV in the treatment of HIV-1 infected ART-naive participants, determined by the achievement and maintenance of confirmed HIV-1 ribonucleic acid (RNA) \< 400 copies/mL (c/mL) through Week 48, as defined by the United States (US) Food and Drug Administration (FDA) time-to-loss-of-virologic-response (TLOVR) algorithm.

Read the detailed description

This study was originally planned as a 48-week, Phase 3, randomized, open-label, multicenter study comparing EFV+FTC+TDF (administered as the individual component drugs) versus CBV (lamivudine/zidovudine) + EFV to assess the efficacy and safety of both treatments in ART-Naive, HIV-1 infected participants. The regimen of CBV (administered twice daily) + EFV (administered once daily) served as the active control treatment and was compared with the regimen of EFV+FTC+TDF; each component drug in the EFV+FTC+TDF regimen was administered once daily.

Week 48 to Week 96:

The study was extended and continued to evaluate the efficacy and safety of the two regimens up to a total treatment duration of 96 weeks. The regimen of EFV+FTC+TDF continued to be dosed as the component drugs (EFV + FTC + TDF), once daily, without regard to meals. The regimen of CBV+EFV was dosed as 2 pills (CBV, twice daily in the morning without regard to meals) + EFV (once daily, without regard to meals).

Week 96 to Week 144:

A further study extension changed the 3-pill EFV+FTC+TDF regimen to a 2-pill regimen of EFV + Truvada ([TVD]: a fixed-dose combination pill containing FTC/TDF), once daily without regard to meals, and continued to evaluate the efficacy and safety of the two regimens for a further 48 weeks up to a total study treatment duration of 144 weeks. The regimen of CBV+EFV continued to be dosed as 2 pills (CBV, twice daily in the morning without regard to meals) + EFV (once daily, without regard to meals).

Week 144 to end of study (Week 240):

A final study extension provided all study participants from both treatment regimens the option to switch their respective treatments to the 1-pill regimen of for a further 96 weeks up to a total study duration of 240 weeks (5 years) to further assess the efficacy and safety of ART regimen simplification. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.

03

Conditions studied

  • HIV Infections

Keywords

  • Human Immunodeficiency Virus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:

  • Plasma -1 RNA levels greater than 10,000 c/mL using Roche Amplicor HIV-1 Monitor Test Version 1.5 Standard
  • Adequate renal function: Calculated greater than or equal to 50 mL/min according to the Cockcroft-Gault Formula.
  • Hepatic transaminases ( [AST] and alanine aminotransferase [ALT]) 3 x (ULN).
  • Total less than or equal to 1.5 mg/dL.
  • Adequate hematologic function ( greater than or equal to 1,000/mm\^3; greater than or equal to 50,000/mm\^3; greater than or equal to 8.0 g/dL).
  • Serum amylase less than or equal to 1.5 x ULN.
  • Serum phosphorus greater than or equal to 2.2 mg/dL.
  • Willingness to use effective by both males and females while on study treatment and for 30 days following study drug completion.
  • greater than or equal to 1 year
  • The ability to understand and sign written form obtained prior to initiation of study procedures.

Exclusion Criteria: Participants were not eligible for entry to the study if any of the following were met:

  • Prior treatment with any non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase inhibitor (NRTI), or protease inhibitor (PI).
  • A new AIDS-defining condition diagnosed (exception CD4 criteria) within 30 days of baseline.
  • Receiving ongoing therapy with any of the following: nephrotoxic agents, probenecid, systemic chemotherapeutic agents, systemic , interleukin-2, drugs that interact with efavirenz. Administration of any of the above medications must be discontinued at least 30 days prior to baseline visit and for duration of study.
  • Pregnant or lactating participants.
  • other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma. Participants with -confirmed KS were eligible but must not have received any systemic therapy for KS within 30 days of baseline and not anticipated starting systemic therapy during the study.
  • Prior history of renal or bone disease.
  • Any other clinical condition prior to therapy that would make the participant unsuitable for the study or unable to comply with the dosing requirements in the opinion of the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
517 participants (actual)

Study arms

  • Active comparator
    EFV+CBV

    Participants in this group received EFV 600 mg once daily + Combivir (\[CBV\]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla (\[ATR\]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.

    Drug: Efavirenz (EFV) · Drug: Lamivudine/zidovudine

  • Experimental
    EFV+FTC+TDF

    Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF \[TDF\]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada (\[TVD\] the fixed-dose combination pill containing FTC/TDF \[200/300 mg\] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.

    Drug: Emtricitabine (FTC) · Drug: Tenofovir Disoproxil Fumarate (TDF) · Drug: Efavirenz (EFV) · Drug: FTC/TDF · Drug: FTC/TDF/EFV

Interventions

  • Capsule containing 200 mg FTC, taken once daily, for 96 weeks

    Also known as: Emtriva

  • Tablet containing 300 mg TDF, taken once daily, for 96 weeks

    Also known as: Viread

  • Tablet containing 600 mg EFV, taken once daily, for 96 weeks

    Also known as: Sustiva

  • DrugFTC/TDF

    Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144

    Also known as: Truvada (TVD)

  • DrugFTC/TDF/EFV

    Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240

    Also known as: Atripla (ATR)

  • DrugLamivudine/zidovudine

    Drug pages: Lamivudine · Zidovudine

    Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks

    Also known as: Combivir (CBV)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm

    Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 48 visit (ie, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 48 visit.

    Time frame: 48 weeks

Secondary outcomes

  1. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)

    Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 48 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 48 visit.

    Time frame: Week 48

  2. Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.

    The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).

    Time frame: 48 weeks

  3. Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 48

    The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).

    Time frame: 48 Weeks

  4. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48

    TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

    Time frame: Baseline to 48 weeks

  5. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48

    TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

    Time frame: Baseline to 48 Weeks

  6. Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48

    Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Baseline to 48 Weeks

  7. Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48

    Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Baseline to 48 Weeks

  8. Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48

    Change from study baseline to Week 48 in HIV-1 RNA in log10 scale (Week 48 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).

    Time frame: Study baseline to Week 48

  9. Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48

    Change from study baseline to Week 48 in CD4 cell count = Week 48 CD4 cell count value minus study baseline CD4 cell count value

    Time frame: Study baseline to Week 48

  10. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)

    Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 96 visit.

    Time frame: 96 Weeks

  11. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)

    Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 96 visit.

    Time frame: Week 96

  12. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96

    TLOVR for participants with confirmed virologic response (2 consecutive HIV-1 RNA \< 400 c/mL) prior to study drug discontinuation, was the time to the earliest of premature study regimen discontinuation, or confirmed HIV-1 RNA \> 400 c/mL (2 consecutive HIV-1 RNA ≥ 400 c/mL, or the last HIV-1 RNA ≥ 400 c/mL followed by premature study regimen discontinuation due to loss to follow-up). Participants who did not achieve confirmed virologic response before premature study regimen discontinuation or last HIV-1 RNA, were assumed to have lost virologic response on Study Day 1.

    Time frame: Week 96

  13. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96

    TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

    Time frame: Week 96

  14. Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96

    Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Week 96

  15. Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96

    Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Week 96

  16. Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96

    Change from study baseline to Week 96 in HIV-1 RNA in log10 scale (Week 96 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).

    Time frame: Study baseline to Week 96

  17. Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96

    Change from study baseline to Week 96 in CD4 cell count = Week 96 CD4 cell count value minus study baseline CD4 cell count value

    Time frame: Baseline to Week 96

  18. Change in Limb Fat (kg) From Week 48 to Week 96

    Change from Week 48 to Week 96 in limb fat = Week 96 limb fat value minus Week 48 limb fat value.

    Time frame: Week 48 to Week 96

  19. Change in Trunk Fat (kg) From Week 48 to Week 96

    Change from Week 48 to Week 96 in trunk fat = Week 96 trunk fat value minus Week 48 trunk fat value

    Time frame: Week 48 to Week 96

  20. Change in Total Body Fat (kg) From Week 48 to Week 96

    Change from Week 48 to Week 96 in total body fat = Week 96 total body fat value minus Week 48 total body fat value

    Time frame: 48 weeks to 96 weeks

  21. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)

    Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 144 visit (i.e., the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV-1 RNA levels \< 400 c/mL prior to Week 144 visit.

    Time frame: 144 weeks

  22. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)

    Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL (c/mL) had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 144 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV-1 RNA levels \< 50 c/mL prior to Week 144 visit.

    Time frame: Week 144

  23. Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144

    The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).

    Time frame: Week 144

  24. Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144

    The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).

    Time frame: Week 144

  25. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144

    TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

    Time frame: Week 144

  26. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144

    TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

    Time frame: Week 144

  27. Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144

    Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Week 144

  28. Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144

    Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Week 144

  29. Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144

    Change from study baseline to Week 144 in HIV-1 RNA in log10 scale (Week 144 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).

    Time frame: Study baseline to Week 144

  30. Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144

    Change from study baseline to Week 144 in CD4 cell count = Week 144 CD4 cell count value minus study baseline CD4 cell count value

    Time frame: Baseline to Week 144

  31. Change in Limb Fat (kg) From Week 48 to Week 144

    Change from Week 48 to Week 144 in limb fat = Week 144 limb fat value minus Week 48 limb fat value

    Time frame: Week 48 to Week 144

  32. Change in Trunk Fat (kg) From Week 48 to Week 144

    Change from Week 48 to Week 144 in trunk fat = Week 144 trunk fat value minus Week 48 trunk fat value

    Time frame: Week 48 to Week 144

  33. Change in Total Body Fat (kg) From Week 48 to Week 144

    Change from Week 48 to Week 144 in total body fat = Week 144 total body fat value minus Week 48 total body fat value

    Time frame: Week 48 to Week 144

  34. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm

    Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 240 visit.

    Time frame: Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)

  35. Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm

    Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 240 visit.

    Time frame: Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)

  36. Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)

    The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).

    Time frame: Week 240 (Atripla Week 96)

  37. Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)

    The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).

    Time frame: Week 240 (Atripla Week 96)

  38. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)

    TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

    Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

  39. Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)

    TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

    Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

  40. Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)

    Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Week 240 (Atripla Week 96)

  41. Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)

    Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

    Time frame: Week 240 (Atripla Week 96)

  42. Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)

    Change from baseline to Week 240 (Atripla Week 96) in CD4 cell count = Week 240 (Atripla Week 96) CD4 cell count value minus baseline CD4 cell count value

    Time frame: Study/Atripla baseline to Week 240 (Atripla Week 96)

  43. Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

    Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in limb fat = Week 240 (Atripla Week 96) limb fat value minus Week 144 (Atripla Baseline) limb fat value

    Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

  44. Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

    Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in trunk fat = Week 240 (Atripla Week 96) trunk fat value minus Week 144 (Atripla Baseline) trunk fat value

    Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

  45. Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

    Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in total body fat = Week 240 (Atripla Week 96) total body fat value minus Week 144 (Atripla Baseline) total body fat value

    Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

  46. Treatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

    Participants were asked: "In general, how satisfied are you with the convenience and simplicity of your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

    Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)

  47. Treatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

    Participants were asked: "In general, how satisfied are you with the ability of your current treatment regimen to control your HIV infection?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

    Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)

  48. Treatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

    Participants were asked: "In general, how satisfied are you with your ability to tolerate your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

    Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)

  49. Treatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

    Participants were asked: "In general, how satisfied are you with your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

    Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)

  50. Treatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

    Participants were asked: "How bothered are you with the side effects of your current treatment regimen?" Possible responses were on a 4-category scale: "does not bother me"; "bothers me a little bit"; "bothers me a lot"; and "bothers me terribly". For the evaluation of the change in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "does not bother me" and "bothers me" ("bothers me" included "bothers me a little bit"; "bothers me a lot"; "bothers me terribly").

    Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)

  51. Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

    The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey: Physical Component Summary (PCS). The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the Mental Component Summary (MCS). PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and SD of 10 (in the general population).

    Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

  52. Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

    The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey MCS. The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the MCS. PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and a SD of 10 (in the general population).

    Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

07

Results

Posted Oct 13, 2010

Participant flow

Participants were enrolled at 70 study sites in the United States and Europe. The first participant was screened on 29 July 2003; the last participant was randomized on 16 January 2004; the last participant observation for the primary endpoint analysis was 11 February 2005; the last participant last visit for end of study analysis was 10 June 2009.

Randomized Phase
Participant flow — Randomized Phase
MilestoneEFV+FTC+TDFCBV+EFV
Started257254
Completed187166
Not completed7088
Withdrew: Lost to follow-up2633
Withdrew: Adverse event1010
Withdrew: Withrawal of consent1018
Withdrew: Sub-optimal virological response313
Withdrew: Noncompliance84
Withdrew: Protocol violation20
Withdrew: Pregnancy31
Withdrew: Death13
Withdrew: Hepatitis c treatment contraindicated01
Withdrew: Inability to swallow pills01
Withdrew: Incarceration32
Withdrew: Moved out of state01
Withdrew: Baseline nnrti resistance mutations40
Withdrew: High hepatitis b dna01
Atripla Phase
Participant flow — Atripla Phase
MilestoneEFV+FTC+TDFCBV+EFV
Started160126
Completed142106
Not completed1820
Withdrew: Adverse event21
Withdrew: Lost to follow-up57
Withdrew: Pregnancy01
Withdrew: Death02
Withdrew: Withdrew consent77
Withdrew: Sub-optimal virological response01
Withdrew: Non-compliance10
Withdrew: Other31

Outcome measures

PrimaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm

Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 48 visit (ie, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 48 visit.

Time frame:
48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm
Percentage of participantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm84.472.8
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.002 (The difference and 95% CI are stratum-weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from the Cochran-Mantel-Haenzel test stratified on baseline CD4 cell count.) · Difference in percentages: 11.4 · 95% CI 4.3 to 18.6No other adjustments were made.
SecondaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)

Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 48 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 48 visit.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)79.570.4
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.021 (The difference and 95% CI are stratum-weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from the Cochran-Mantel-Haenzel test stratified on baseline CD4 cell count.) · Difference in percentages: 9.1 · 95% CI 1.6 to 16.6No other adjustments were made.
SecondaryPercentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.

The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).

Time frame:
48 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.80.469.3
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.004 (The difference and 95% CI are stratum-weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from the Cochran-Mantel-Haenzel test stratified on baseline CD4 cell count.) · Difference in percentages: 11.2 · 95% CI 3.7 to 18.6No other adjustments were made
SecondaryPercentage of Participants With HIV-1 RNA < 50 c/mL at Week 48

The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).

Time frame:
48 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 48
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 4874.566.9
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.058 (The difference and 95% CI are stratum-weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from the Cochran-Mantel-Haenzel test stratified on baseline CD4 cell count.) · Difference in percentages: 7.9 · 95% CI 0.1 to 15.6No other adjustments were made.
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48

TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

Time frame:
Baseline to 48 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 481930
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.003 (The distribution of time to loss-of-virologic response was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48

TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

Time frame:
Baseline to 48 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 482332
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.046 (The distribution of time to loss-of-virologic response was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48

Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Baseline to 48 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48916
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.026 (The distribution of pure virological failure was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48

Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Baseline to 48 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48
Percentage of participantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 481624
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.063 (The distribution of pure virological failure was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryChange From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48

Change from study baseline to Week 48 in HIV-1 RNA in log10 scale (Week 48 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).

Time frame:
Study baseline to Week 48
Reported as:
Mean · Log10 c/mL
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48
Log10 c/mLEFV+FTC+TDFCBV+EFV
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48-3.31 ± 0.54-3.26 ± 0.58
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Van Elteren · p = 0.31 (The change from baseline to Week 48 in HIV-1 RNA was compared between the 2 treatment groups using baseline CD4 stratum-weighted CI around the mean difference. P-value is from stratum-weighted Van Elteren test.) · Mean difference (net): -0.05 · 95% CI -0.16 to 0.06No other adjustments were made.
SecondaryChange From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48

Change from study baseline to Week 48 in CD4 cell count = Week 48 CD4 cell count value minus study baseline CD4 cell count value

Time frame:
Study baseline to Week 48
Reported as:
Mean · CD4 Cell Count (cells/mm^3)
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48
CD4 Cell Count (cells/mm^3)EFV+FTC+TDFCBV+EFV
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48190 ± 111.7158 ± 107.3
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Van Elteren · p = 0.002 (The change from baseline to Week 48 in HIV-1 RNA was compared between the 2 treatment groups using baseline CD4 stratum-weighted CI around the mean difference. P-value is from stratum weighted Van Elteren test.) · Stratum-weighted difference: 31.74 · 95% CI 8.96 to 54.52No other adjustments were made.
SecondaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)

Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 96 visit.

Time frame:
96 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)74.661.9
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.004 (The difference and 95% CI are stratum weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from Cochran-Mantel-Haenszel test stratified on baseline CD4 cell count.) · Difference in percentages: 12.7 · 95% CI 4.3 to 21.1No other adjustments were made.
SecondaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)

Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 96 visit.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)67.260.9
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.158 (The difference and 95% CI are stratum weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from Cochran-Mantel-Haenszel test stratified on baseline CD4 cell count.) · Difference in proportions: 6.4 · 95% CI -2.3 to 15.0No other adjustments were made.
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96

TLOVR for participants with confirmed virologic response (2 consecutive HIV-1 RNA \< 400 c/mL) prior to study drug discontinuation, was the time to the earliest of premature study regimen discontinuation, or confirmed HIV-1 RNA \> 400 c/mL (2 consecutive HIV-1 RNA ≥ 400 c/mL, or the last HIV-1 RNA ≥ 400 c/mL followed by premature study regimen discontinuation due to loss to follow-up). Participants who did not achieve confirmed virologic response before premature study regimen discontinuation or last HIV-1 RNA, were assumed to have lost virologic response on Study Day 1.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 962537
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.003 (The distribution of time to loss-of-virologic response was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96

TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 963238
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.124 (The distribution of time to loss-of-virologic response was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96

Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96917
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.025 (The distribution of pure virological failure was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96

Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 962023
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.41 (The distribution of pure virological failure was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryChange From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96

Change from study baseline to Week 96 in HIV-1 RNA in log10 scale (Week 96 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).

Time frame:
Study baseline to Week 96
Reported as:
Mean · Log10 c/mL
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96
Log10 c/mLEFV+FTC+TDFCBV+EFV
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96-3.30 ± 0.57-3.25 ± 0.59
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Van Elteren · p = 0.45 (The change from baseline to Week 96 in HIV-1 RNA was compared between the 2 treatment groups using baseline CD4 stratum-weighted CI around the mean difference.) · Stratum-weighted difference: -0.05 · 95% CI -0.17 to 0.08No other adjustments were made.
SecondaryChange From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96

Change from study baseline to Week 96 in CD4 cell count = Week 96 CD4 cell count value minus study baseline CD4 cell count value

Time frame:
Baseline to Week 96
Reported as:
Mean · CD4 Cell Count (cells/mm^3)
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96
CD4 Cell Count (cells/mm^3)EFV+FTC+TDFCBV+EFV
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96270 ± 147.5237 ± 136.4
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Van Elteren · p = 0.036 (The change from baseline to Week 96 in CD4 cell count was compared between the 2 treatment groups using baseline CD4 stratum-weighted CI around the mean difference. P-value is from stratum weighted Van Elteren test.) · Stratum-weighted difference: 32.93 · 95% CI 0.87 to 64.99No other adjustments were made.
SecondaryChange in Limb Fat (kg) From Week 48 to Week 96

Change from Week 48 to Week 96 in limb fat = Week 96 limb fat value minus Week 48 limb fat value.

Time frame:
Week 48 to Week 96
Reported as:
Mean · limb fat (kg)
Change in Limb Fat (kg) From Week 48 to Week 96
limb fat (kg)EFV+FTC+TDFCBV+EFV
Change in Limb Fat (kg) From Week 48 to Week 960.74 ± 1.60-0.77 ± 1.58
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Wilcoxon Rank Sum Test · p = <0.001 (The change from Week 48 to Week 96 in limb fat was compared between the 2 treatment groups; the P-value is from the Wilcoxon Rank Sum Test.)No other adjustments were made.
SecondaryChange in Trunk Fat (kg) From Week 48 to Week 96

Change from Week 48 to Week 96 in trunk fat = Week 96 trunk fat value minus Week 48 trunk fat value

Time frame:
Week 48 to Week 96
Reported as:
Mean · trunk fat (kg)
Change in Trunk Fat (kg) From Week 48 to Week 96
trunk fat (kg)EFV+FTC+TDFCBV+EFV
Change in Trunk Fat (kg) From Week 48 to Week 960.94 ± 2.30-0.04 ± 1.65
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Wilcoxon Rank Sum test · p = 0.025 (The change from Week 48 to Week 96 in trunk fat was compared between the 2 treatment groups; the P-value is from the Wilcoxon Rank Sum Test.)No other adjustments were made.
SecondaryChange in Total Body Fat (kg) From Week 48 to Week 96

Change from Week 48 to Week 96 in total body fat = Week 96 total body fat value minus Week 48 total body fat value

Time frame:
48 weeks to 96 weeks
Reported as:
Mean · total body fat (kg)
Change in Total Body Fat (kg) From Week 48 to Week 96
total body fat (kg)EFV+FTC+TDFCBV+EFV
Change in Total Body Fat (kg) From Week 48 to Week 961.69 ± 3.80-0.82 ± 3.01
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Wilcoxon Rank Sum test · p = <0.001 (The change from Week 48 to Week 96 in trunk fat was compared between the 2 treatment groups; the P-value is from the Wilcoxon Rank Sum Test.)No other adjustments were made.
SecondaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)

Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 144 visit (i.e., the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV-1 RNA levels \< 400 c/mL prior to Week 144 visit.

Time frame:
144 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)70.958.1
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.004 (The difference and 95% CI are stratum weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from Cochran-Mantel-Haenzel test.) · Difference in proportions: 12.9 · 95% CI 4.2 to 21.6No other adjustments were made.
SecondaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)

Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL (c/mL) had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 144 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV-1 RNA levels \< 50 c/mL prior to Week 144 visit.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
Percentage of participantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)64.356.3
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.082 (The difference and 95% CI are stratum weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from the Cochran-Mantel-Haenszel test stratified on baseline CD4 cell count.) · Difference in proportions: 8.1 · 95% CI -0.8 to 17.0No other adjustments were made.
SecondaryPercentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144

The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 14463.151.6
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.009 (The difference and 95% CI are stratum weighted on baseline CD4 using normal approximation. The p-value for the superiority test is from Cochran-Mantel-Haenzel test stratified on baseline CD4 cell count.) · Difference in proportions: 11.6 · 95% CI 3.1 to 20.1No other adjustments were made.
SecondaryPercentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144

The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 14460.850.4
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Cochran-Mantel-Haenszel · p = 0.019 (The p-value for the superiority test is from Cochran-Mantel-Haenzel test stratified on baseline CD4 cell count.) · Difference in proportions: 10.4 · 95% CI 1.8 to 19.0No other adjustments were made.
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144

TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 1442841
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.003 (The distribution of loss of virological response was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144

TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 1443443
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.056 (The distribution of pure virological failure was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144

Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144
Percentage of participantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 1441117
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.066 (The distribution of pure virological failure was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryPercentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144

Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Week 144
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144
Percentage of ParticipantsEFV+FTC+TDFCBV+EFV
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 1442125
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Log Rank · p = 0.30 (The distribution of pure virological failure was estimated using the Kaplan-Meier product limit method and compared between treatment groups using a baseline CD4 stratum-weighted log-rank test.)No other adjustments were made.
SecondaryChange From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144

Change from study baseline to Week 144 in HIV-1 RNA in log10 scale (Week 144 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).

Time frame:
Study baseline to Week 144
Reported as:
Mean · Log10 c/mL
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144
Log10 c/mLEFV+FTC+TDFCBV+EFV
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144-3.32 ± 0.54-3.30 ± 0.52
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Van Elteren · p = 0.39 (The change from baseline to Week 144 in HIV-1 RNA was compared between the 2 treatment groups using baseline CD4 stratum-weighted CI around the mean difference. P-value is from a stratum weighted Van Elteren test.) · Mean difference (net): -0.04 · 95% CI -0.16 to 0.08No other adjustments were made
SecondaryChange From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144

Change from study baseline to Week 144 in CD4 cell count = Week 144 CD4 cell count value minus study baseline CD4 cell count value

Time frame:
Baseline to Week 144
Reported as:
Mean · CD4 Cell Count (cells/mm^3)
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144
CD4 Cell Count (cells/mm^3)EFV+FTC+TDFCBV+EFV
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144312 ± 161.2271 ± 147.4
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Van Elteren · p = 0.089 (The change from baseline to Week 144 in CD4 cell count was compared between the 2 treatment groups using baseline CD4 stratum-weighted CI around the mean difference. P-value is from a stratum weighted Van Elteren test.) · Mean difference (net): 41.30 · 95% CI 4.05 to 78.55No other adjustments were made
SecondaryChange in Limb Fat (kg) From Week 48 to Week 144

Change from Week 48 to Week 144 in limb fat = Week 144 limb fat value minus Week 48 limb fat value

Time frame:
Week 48 to Week 144
Reported as:
Mean · limb fat (kg)
Change in Limb Fat (kg) From Week 48 to Week 144
limb fat (kg)EFV+FTC+TDFCBV+EFV
Change in Limb Fat (kg) From Week 48 to Week 1441.13 ± 1.93-1.09 ± 1.72
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Wilcoxon Rank Sum test · p = 0.001 (P-value is from the Wilcoxon Rank Sum Test)No other adjustments were made
SecondaryChange in Trunk Fat (kg) From Week 48 to Week 144

Change from Week 48 to Week 144 in trunk fat = Week 144 trunk fat value minus Week 48 trunk fat value

Time frame:
Week 48 to Week 144
Reported as:
Mean · trunk fat (kg)
Change in Trunk Fat (kg) From Week 48 to Week 144
trunk fat (kg)EFV+FTC+TDFCBV+EFV
Change in Trunk Fat (kg) From Week 48 to Week 1441.30 ± 2.40-0.10 ± 1.79
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Wilcoxon Rank Sum test · p = 0.011 (P-value is from the Wilcoxon Rank Sum Test)No other adjustments were made
SecondaryChange in Total Body Fat (kg) From Week 48 to Week 144

Change from Week 48 to Week 144 in total body fat = Week 144 total body fat value minus Week 48 total body fat value

Time frame:
Week 48 to Week 144
Reported as:
Mean · total body fat (kg)
Change in Total Body Fat (kg) From Week 48 to Week 144
total body fat (kg)EFV+FTC+TDFCBV+EFV
Change in Total Body Fat (kg) From Week 48 to Week 1442.47 ± 4.22-1.18 ± 3.37
Statistical analysis
  • EFV+FTC+TDF vs CBV+EFV · Wilcoxon Rank Sum test · p = <0.001 (P-value is from the Wilcoxon Rank Sum Test)No other adjustments were made
SecondaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm

Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 240 visit.

Time frame:
Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
Percentage of ParticipantsAll Atripla
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm87
SecondaryPercentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm

Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 240 visit.

Time frame:
Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
Percentage of ParticipantsAll Atripla
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm85
SecondaryPercentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)

The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).

Time frame:
Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)
Percentage of ParticipantsEFV+FTC+TDF/Atripla (From Study Baseline)All Atripla (From Atripla Baseline)
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)8785
SecondaryPercentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)

The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).

Time frame:
Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)
Percentage of ParticipantsEFV+FTC+TDF/Atripla (From Study Baseline)All Atripla (From Atripla Baseline)
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)8482
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)

TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

Time frame:
Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
Percentage of ParticipantsAll Atripla
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)13
SecondaryPercentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)

TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.

Time frame:
Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
Percentage of ParticipantsAll Atripla
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)15
SecondaryPercentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)

Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)
Percentage of ParticipantsEFV+FTC+TDF/Atripla (From Study Baseline)All Atripla (From Atripla Baseline)
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)112
SecondaryPercentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)

Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.

Time frame:
Week 240 (Atripla Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)
Percentage of ParticipantsEFV+FTC+TDF/Atripla (From Study Baseline)All Atripla (From Atripla Baseline)
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)224
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)

Change from baseline to Week 240 (Atripla Week 96) in CD4 cell count = Week 240 (Atripla Week 96) CD4 cell count value minus baseline CD4 cell count value

Time frame:
Study/Atripla baseline to Week 240 (Atripla Week 96)
Reported as:
Mean · CD4 Cell count (Cells/mm^3)
Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)
CD4 Cell count (Cells/mm^3)EFV+FTC+TDF/Atripla (From Study Baseline)All Atripla (From Atripla Baseline)
Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)346 ± 197.242 ± 148.2
SecondaryChange in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in limb fat = Week 240 (Atripla Week 96) limb fat value minus Week 144 (Atripla Baseline) limb fat value

Time frame:
Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Reported as:
Mean · limb fat (kg)
Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
limb fat (kg)All Atripla
Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)0.12 ± 1.657
Statistical analysis
  • All Atripla · Wilcoxon Signed Rank test · p = 0.16 (P-value is from the Wilcoxon Signed Rank test. No adjustments for multiple comparisons were made)
SecondaryChange in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in trunk fat = Week 240 (Atripla Week 96) trunk fat value minus Week 144 (Atripla Baseline) trunk fat value

Time frame:
Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Reported as:
Mean · trunk fat (kg)
Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
trunk fat (kg)All Atripla
Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)0.27 ± 2.242
Statistical analysis
  • All Atripla · Wilcoxon Signed Rank test · p = 0.049 (P-value is from the Wilcoxon Signed Rank test. No adjustments for multiple comparisons were made)
SecondaryChange in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in total body fat = Week 240 (Atripla Week 96) total body fat value minus Week 144 (Atripla Baseline) total body fat value

Time frame:
Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Reported as:
Mean · total body fat (kg)
Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
total body fat (kg)All Atripla
Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)0.37 ± 3.747
Statistical analysis
  • All Atripla · Wilcoxon Signed Rank test · p = 0.055 (P-value is from the Wilcoxon Signed Rank test. No adjustments for multiple comparisons were made)
SecondaryTreatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

Participants were asked: "In general, how satisfied are you with the convenience and simplicity of your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

Time frame:
Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Reported as:
Number · Participants
Treatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
ParticipantsAll Atripla
Very satisfied (W 144 and W 240)182
Not very satisfied (W 144 and W 240)6
Very satisfied (W 144); not very satisfied (W 240)8
Not very satisfied (W 144); very satisfied (W 240)29
Statistical analysis
  • All Atripla · McNemar · p = <0.001 (The number and proportion of participants in each category ("very satisfied", "not very satisfied") were summarized. The P-value for the category shift from Week 144 baseline within a treatment group was calculated using the McNemar test.)
SecondaryTreatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

Participants were asked: "In general, how satisfied are you with the ability of your current treatment regimen to control your HIV infection?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

Time frame:
Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Reported as:
Number · Participants
Treatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
ParticipantsAll Atripla
Very satisfied (W 144 and W 240)192
Not very satisfied (W 144 and W 240)8
Very satisfied (W 144); not very satisfied (W 240)9
Not very satisfied (W 144); very satisfied (W 240)17
Statistical analysis
  • All Atripla · McNemar · p = 0.12 (The number and proportion of participants in each category ("very satisfied", "not very satisfied") were summarized. The P-value for the category shift from Week 144 baseline within a treatment group was calculated using the McNemar test.)
SecondaryTreatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

Participants were asked: "In general, how satisfied are you with your ability to tolerate your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

Time frame:
Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Reported as:
Number · Participants
Treatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
ParticipantsAll Atripla
Very satisfied (W 144 and W 240)166
Not very satisfied (W 144 and W 240)21
Very satisfied (W 144); not very satisfied (W 240)13
Not very satisfied (W 144); very satisfied (W 240)26
Statistical analysis
  • All Atripla · McNemar · p = 0.037 (The number and proportion of participants in each category ("very satisfied", "not very satisfied") were summarized. The P-value for the category shift from Week 144 baseline within a treatment group was calculated using the McNemar test.)
SecondaryTreatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

Participants were asked: "In general, how satisfied are you with your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").

Time frame:
Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Reported as:
Number · Participants
Treatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
ParticipantsAll Atripla
Very satisfied (W 144 and W 240)180
Not very satisfied (W 144 and W 240)10
Very satisfied (W 144); not very satisfied (W 240)9
Not very satisfied (W 144); very satisfied (W 240)23
Statistical analysis
  • All Atripla · McNemar · p = 0.013 (The number and proportion of participants in each category ("very satisfied", "not very satisfied") were summarized. The P-value for the category shift from Week 144 baseline within a treatment group was calculated using the McNemar test.)
SecondaryTreatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.

Participants were asked: "How bothered are you with the side effects of your current treatment regimen?" Possible responses were on a 4-category scale: "does not bother me"; "bothers me a little bit"; "bothers me a lot"; and "bothers me terribly". For the evaluation of the change in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "does not bother me" and "bothers me" ("bothers me" included "bothers me a little bit"; "bothers me a lot"; "bothers me terribly").

Time frame:
Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Reported as:
Number · Participants
Treatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
ParticipantsAll Atripla
Bothers me (W 144 and W 240)41
Does not bother me (W 144 and W 240)126
Bothers me (W 144); does not bother me (W 240)31
Does not bother me (W 144); bothers me (W 240)28
Statistical analysis
  • All Atripla · McNemar · p = 0.70 (The number and proportion of participants in each category ("bothers", "does not bother") were summarized. The P-value for the category shift from Week 144 baseline within a treatment group was calculated using the McNemar test.)
SecondaryQuality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey: Physical Component Summary (PCS). The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the Mental Component Summary (MCS). PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and SD of 10 (in the general population).

Time frame:
Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Reported as:
Mean · Composite Score
Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Composite ScoreAll Atripla
Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)0.0 ± 6.80
Statistical analysis
  • All Atripla · Wilcoxon Signed Rank Test · p = 0.95 (P-value is from the Wilcoxon Signed Rank Test.)
SecondaryQuality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)

The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey MCS. The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the MCS. PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and a SD of 10 (in the general population).

Time frame:
Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Reported as:
Mean · Composite Score
Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Composite ScoreAll Atripla
Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)0.9 ± 8.65
Statistical analysis
  • All Atripla · Wilcoxon Signed Rank Test · p = 0.23 (P-value is from the Wilcoxon Signed Rank Test)

Adverse events

Collected over Adverse events (AEs) were reported during the 144-week randomized treatment phase (FTC+TDF+EFV and CBV+EFV groups) and for the 96-week non-randomized Atripla extension phase (for all participants who opted to switch to Atripla).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FTC+TDF+EFV (Baseline to 144 Weeks)—29/257 (11.3%)233/257 (90.7%)
FTC+TDF+EFV/ATR (Baseline to 240 Weeks)—24/160 (15%)152/160 (95%)
CBV+EFV (Baseline to 144 Weeks)—35/254 (13.8%)222/254 (87.4%)
All Atripla (Week 144 to 240)—14/286 (4.9%)190/286 (66.4%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventFTC+TDF+EFV (Baseline to 144 Weeks)FTC+TDF+EFV/ATR (Baseline to 240 Weeks)CBV+EFV (Baseline to 144 Weeks)All Atripla (Week 144 to 240)
AnaemiaBlood and lymphatic system disorders0/2570/1607/2540/286
PneumoniaInfections and infestations2/2573/1602/2541/286
AppendicitisInfections and infestations2/2572/1602/2540/286
NephrolithiasisRenal and urinary disorders2/2572/1600/2540/286
Subcutaneous AbscessInfections and infestations0/2572/1600/2542/286
Staphylococcal AbscessInfections and infestations0/2570/1602/2540/286
AlcoholismPsychiatric disorders1/2571/1600/2540/286
Anal Cancer MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2571/1600/2541/286
Benign Prostatic HyperplasiaReproductive system and breast disorders0/2571/1600/2541/286
Dental CariesGastrointestinal disorders1/2571/1600/2540/286
Most frequent other events
Showing 10 of 55
Most frequent other events
EventFTC+TDF+EFV (Baseline to 144 Weeks)FTC+TDF+EFV/ATR (Baseline to 240 Weeks)CBV+EFV (Baseline to 144 Weeks)All Atripla (Week 144 to 240)
DiarrhoeaGastrointestinal disorders73/25757/16050/25429/286
NauseaGastrointestinal disorders66/25737/16083/2546/286
DizzinessNervous system disorders71/25750/16074/2549/286
NasopharyngitisInfections and infestations45/25749/16033/25442/286
Upper Respiratory Tract InfectionInfections and infestations48/25749/16027/25430/286
HeadacheNervous system disorders51/25740/16043/25416/286
InsomniaPsychiatric disorders44/25738/16045/25422/286
SinusitisInfections and infestations33/25735/16017/25419/286
FatigueGeneral disorders46/25734/16046/25414/286
Abnormal DreamsPsychiatric disorders45/25733/16034/2543/286

Baseline characteristics

Age Continuous
Age Continuous(years)EFV+FTC+TDFCBV+EFVTotal
Mean38 ± 9.938 ± 9.038 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)EFV+FTC+TDFCBV+EFVTotal
Female363369
Male219221440
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EFV+FTC+TDFCBV+EFVTotal
White142156298
Black6551116
Hispanic394079
Asian336
Not allowed to report011
Other639
HIV Status
HIV Status(Participants)EFV+FTC+TDFCBV+EFVTotal
Asymptomatic332659
Symptomatic HIV Infection117127244
AIDS105101206
CD4 cell count
CD4 cell count(Cells/mm^3)EFV+FTC+TDFCBV+EFVTotal
Mean246 ± 171.9245 ± 156.6245 ± 164.2
HIV-1 RNA
HIV-1 RNA(Log10 c/mL)EFV+FTC+TDFCBV+EFVTotal
Mean5.03 ± 0.545.00 ± 0.515.01 ± 0.52
08

Study locations

5 sites
  • AIDS Healthcare Foundation Research
    Beverly Hills, California 90211, United States
  • Capital Medical Associates, P.C.
    Washington, District of Columbia 20036, United States
  • Orlando Immunology Center
    Orlando, Florida 32804, United States
  • NorthStar Medical Center
    Chicago, Illinois 60657, United States
  • Jemsek Clinic
    Huntersville, North Carolina 28078, United States
09

References and documents

Publications

  • Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006 Jan 19;354(3):251-60. doi: 10.1056/NEJMoa051871. PubMed 16421366 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Feb 2005 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2005
First posted
May 30, 2005
Start
Jul 2003
Primary completionActual
Feb 2005
CompletionActual
Jun 2009
Results first posted
Oct 13, 2010
Last update
Oct 13, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00112047
Lead sponsor
Gilead Sciences
First posted
May 30, 2005
Start date
Jul 2003
Primary completion
Feb 2005
Completion
Jun 2009
Results posted
Oct 13, 2010
Last update
Oct 13, 2010

Study contacts

Andrew Cheng, MD, PhD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emtricitabine · Tenofovir

Start the discussion